
Sign up to save your podcasts
Or


Host: Gail J. Roboz, MD, Weill Cornell Medicine
Guest: Aravind Ramakrishnan, MD, St. David’s South Austin Medical Center
This episode is supported by the National Marrow Donor Program (NMDP)
Episode Summary:
For years, allogeneic stem cell transplant was seen mainly as an option for younger patients with AML who could tolerate intensive chemotherapy. That picture is changing fast. Leukemia specialist, Dr. Gail Roboz and transplant physician, Dr. Aravind Ramakrishnan, make the case that every patient who might be a reasonable transplant candidate should be connected with a transplant team early, with HLA typing done at diagnosis.
HOST:
Gail J. Roboz, MD
Professor of Medicine
Director, Leukemia Program, Weill Cornell Medicine
NewYork-Presbyterian Hospital
GUEST:
Aravind Ramakrishnan, MD
Adult Bone Marrow Transplant Medical Director, St. David’s South Austin Medical Center
Texas Transplant Institute, Center for Blood Cancers and Oncology
Topics Covered:
Related Resources:
Connect With Us:
The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Society of Hematologic Oncology.
Host: Joshua Brody, MD, Icahn School of Medicine at Mount Sinai
Guest: Jeremy Abramson, MD, MMSC, Harvard Medical School
This episode is supported by an educational grant from Genentech.
Episode Summary:
Until recently, patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who couldn't have a transplant had no curative options. Today, nearly every patient in the second line can be treated with curative intent. Dr. Josh Brody and Dr. Jeremy Abramson walk through the options: CAR T-cell therapy, bispecific antibodies, antibody-drug conjugates (ADCs), and combinations of these. They cover how to choose the optimal therapy for transplant-ineligible patients, especially when CAR T is not an option or if the disease is progressing rapidly. They also discuss the role of MRD testing in monitoring treatment response, long-term infection risk with bispecific antibodies, and practical tips for coordination of care between academic centers and community oncologists.
HOST:
Joshua Brody, MD
Director, Lymphoma Immunotherapy Program
Icahn School of Medicine at Mount Sinai
Hess Center for Science and Medicine
@JoshuaBrodyMD
LinkedIn
GUEST:
Jeremy Abramson, MD, MMSC
Director, Jon and Jo Ann Hagler Center for Lymphoma
Professor of Medicine, Harvard Medical School
LinkedIn
Topics Covered:
Related Resources:
Connect With Us:
The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Society of Hematologic Oncology.
Host: Nicholas J. Short, MD, MD Anderson Cancer Center
Guest: Jae Park, MD, Memorial Sloan Kettering Cancer Center
This podcast episode is supported by Autolus.
Episode Summary:
This episode of SOHO Spotlight explores the evolving role of CD19 CAR T-cell therapy in adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), highlighting the importance of early referral, patient selection criteria, and differences between currently available CAR T products. Dr. Jae Park and Dr. Nicholas Short discuss emerging evidence supporting safer outpatient treatment, individualized decisions regarding stem cell transplant after CAR T therapy, and the potential for CAR T to move into earlier lines of treatment, with the goal of improving long-term outcomes while reducing the need for intensive chemotherapy and transplantation.
HOST:
Nicholas J. Short, MD
Associate Professor
MD Anderson Cancer Center
Houston, Texas, USA
Dr. Nicholas J. Short is an Associate Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center. He is a nationally recognized leukemia specialist whose research focuses on acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), measurable residual disease (MRD), and the development of novel immunotherapy-based treatments.
Connect with Dr. Short:
GUEST:
Jae Park, MD
Chief, Cellular Therapy Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York, USA
Dr. Jae Park is Chief of the Cellular Therapy Service and Director of the Adult Acute Lymphoblastic Leukemia Program at Memorial Sloan Kettering Cancer Center. An internationally recognized expert in cellular therapies and immunotherapy for hematologic malignancies, his research focuses on developing safer and more effective CAR T-cell therapies to improve outcomes for patients with leukemia.
To view all resources for this episode, view the episode page HERE.
Connect With Us:
The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Society of Hematologic Oncology.
From the publisher's feed
The official educational podcast of the Society of Hematologic Oncology. Expert conversations on the latest in leukemia, lymphoma, myeloma, and beyond — plus practical guidance and clinical updates…